Chris is an intellectual property attorney who focuses primarily on patent litigation in the life sciences and technology sectors. He has experience advising clients on litigations involving pharmaceuticals and related technologies such as medical devices and has counseled clients on regulatory issues relating to the FDA approval of drug products. His work on behalf of drug manufacturers and universities includes representing both plaintiffs and defendants in Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) litigations and extensive practice before the Patent Trial and Appeal Board (PTAB).
Chris has been involved in all aspects of district court litigation, from pre-litigation diligence through trial and has worked on multiple trial teams in various district courts across the country. Additionally, Chris has experience drafting multiple Federal Circuit and Supreme Court filings, including both merits briefs on his cases and amicus briefs regarding the proper interpretation of statutes governing the regulation and approval of pharmaceutical products. Chris has also been involved in multiple suits arising under the Administrative Procedure Act, both assisting clients challenging agency actions and representing clients defending them.
Chris’ knowledge gained earning his undergraduate degree in molecular and cellular biology and experience litigating chemical, pharmaceutical and other life-sciences-related patents allow him to work with a broad array of clients across multiple technological sectors and quickly become familiar with the technologies at issue in such cases.